Nephrol Dial Transplant (1999) 14: 2698-2703
© 1999 European Renal Association-European Dialysis and Transplant Association
Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation
1 Department of Renal Medicine and 2 Conjoint Renal Laboratory, Royal Brisbane and Keperra Hospitals, Brisbane, Australia
Correspondence and offprint requests to: Dr David Saltissi, Department of Renal Medicine, Royal Brisbane Hospital, Herston 4029, Queensland, Australia.
Background. Low-molecular-weight heparin (LMWH) has been suggested as providing safe, efficient, convenient and possibly more cost-effective anticoagulation for haemodialysis (HD) than unfractionated heparin, with fewer side-effects and possible benefits on uraemic dyslipidaemia.
Methods. In this prospective, randomized, cross-over study we compared the safety, clinical efficacy and cost effectiveness of Clexane (enoxaparin sodium; Rhône-Poulenc Rorer) with unfractionated heparin in 36 chronic HD patients. They were randomly assigned to either Clexane (1 mg/kg body weight, equivalent to 100 IU) or standard heparin, and followed prospectively for 12 weeks (36 dialyses) before crossing over to the alternate therapy for a further 12 weeks. Heparin anticoagulation was monitored using activated coagulation times.
Results. Dialysis with Clexane resulted in less frequent minor fibrin/clot formation in the dialyser and lines than with heparin (P<0.001), but was accompanied by increased frequency of minor haemorrhage between dialyses (P<0.001). Clexane dose reduction (to a mean of 0.69 mg/kg) eliminated excess minor haemorrhage without increasing clotting frequencies. Mean vascular compression times were similar in both groups. Over 24 weeks, no changes in standard serum lipid profiles were observed.
Conclusions. This study suggests that a single-dose protocol of Clexane is an effective and very convenient alternative to sodium heparin, but currently direct costs are about 16% more. We recommend an initial dose of 0.70 mg/kg.
Keywords: anticoagulation; haemodialysis; heparin; lipids; low-molecular-weight heparins
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Naumnik, K. Pawlak, and M. Mys'liwiec Unfractionated Heparin but Not Enoxaparin Causes Delayed Plasma PAI-1 Depletion in Hemodialysis Patients: A Prospective Study Clinical and Applied Thrombosis/Hemostasis, February 1, 2009; 15(1): 84 - 91. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Naumnik, J. Borawski, K. Pawlak, and M. Mysliwiec Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-{beta}1 during haemodialysis: a cross-over study Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1690 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lim, D. J. Cook, and M. A. Crowther Safety and Efficacy of Low Molecular Weight Heparins for Hemodialysis in Patients with End-Stage Renal Failure: A Meta-analysis of Randomized Trials J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3192 - 3206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aggarwal, D. A. Whitaker, J. M. Rimmer, R. J. Solomon, F. J. Gennari, B. E. Sobel, and D. J. Schneider Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1559 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Guillet, N. Simon, J. J. Sampol, A.-M. Lorec-Penet, H. Portugal, Y. Berland, B. Dussol, and P. Brunet Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis Nephrol. Dial. Transplant., November 1, 2003; 18(11): 2348 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Naumnik, J. Borawski, and M. Mysliwiec Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study Nephrol. Dial. Transplant., July 1, 2003; 18(7): 1376 - 1382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Taraktchoglou, A. A. Pacey, J. E. Turnbull, and A. Eley Infectivity of Chlamydia trachomatis Serovar LGV but Not E Is Dependent on Host Cell Heparan Sulfate Infect. Immun., February 1, 2001; 69(2): 968 - 976. [Abstract] [Full Text] [PDF]
|
|